Treatment before surgery for advanced low rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a targeted therapy to standard chemotherapy and immunotherapy before surgery helps shrink advanced low rectal tumors more effectively. It aims to improve surgical outcomes and reduce the chance of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with locally advanced rectal cancer that has not spread to other organs.
- You have not had previous treatment for rectal cancer, such as radiation, chemotherapy, or surgery.
- You are able to take oral medications and are in generally good health (able to do daily activities).
- You are willing to undergo surgery after the pre-treatment period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy given before surgery for low rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients with a specific type of cancer that is microsatellite stable (MSS).
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
This trial tests whether adding two newer drugs to standard chemotherapy before surgery can shrink rectal tumors more effectively. It is for patients whose tumors are not too low in the rectum and have certain genetic markers.
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests combining standard chemotherapy and radiation with an immunotherapy drug (QL1706) before surgery for low rectal cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.